MEDITECH joins an increasing roster of prominent EHR companies to certify the healthcare device on its platform to meet the communication needs of medical organizations today and tomorrow.
Pamela Crandall, Senior Marketing Solution Manager at MEDITECH, says: “The Ascom Myco 3 device gives our customers another powerful option for accessing our Expanse Point of Care and wireless phlebotomy solutions through Dryrain's Enterprise browser. Nurses appreciate the mobility of using smartphone devices and the additional facetime it gives them with patients.”
Phlebotomists can also use the Ascom Myco 3 to access MEDITECH’s phlebotomy handheld solution to access a real-time list of specimens awaiting collection and print labels at the patient’s bedside. In addition, phlebotomists can use the barcode scanner to verify patient identification prior to specimen draw.
Francis Schmeer, Chief Sales Officer of Ascom, underlines: “We are delighted to partner with MEDITECH, a leading vendor and founder of the EHR market. The Ascom Myco 3, sold globally and in trials in many leading hospitals, is showing great results across the care continuum. Our aim with this smartphone designed for healthcare professionals is to provide mobility with confidence and improve clinician workflows at the point of care.”
For more information on the Ascom Myco 3 smartphone visit the website here.
This document does not constitute an offer or solicitation to subscribe for, purchase or sell any securities. This document is not being issued in the United States of America or the United Kingdom and should not be distributed in any jurisdiction in a manner where such distribution would not comply with regulatory requirements. In particular, this document may not be distributed into the United States, to United States persons or to publications with a general circulation in the United States. In addition, the securities of Ascom have not been and will not be registered in any jurisdiction outside Switzerland. The securities of Ascom may not be offered, sold or delivered and no solicitation to purchase such securities may be made within the United States or to U.S. persons absent an applicable exemption from the registration requirements of the United States securities laws or within any other jurisdiction and in a manner where such offer, sale, delivery or solicitation might not be in compliance with regulatory requirements (including the United Kingdom).